FDMT 4D Molecular Therapeutics, Inc.companySEC Filings & Insider Trading Activity 2026
Latest 4D Molecular Therapeutics, Inc. (FDMT) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 18, 2026, a 10-Q quarterly report filed on November 10, 2025, an 8-K current report filed on March 30, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for 4D Molecular Therapeutics, Inc. (FDMT) (SEC CIK 1650648), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 2.02: Results of Operations and Financial Condition
- • Full year 2025 financial results announced, details in press release titled “4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones”
- • Press release furnished as Exhibit, key financial and operational updates available there
Recent 8-K FilingsCurrent Reports
AI-powered analysis of 4D Molecular Therapeutics, Inc. (FDMT) 8-K current reports disclosing material events.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Mar 30, 2026 | — | — | — |
8-K | Mar 18, 2026 | — | Analysis | — |
10-K | Mar 18, 2026 | Dec 31, 2025 | — | |
8-K | Jan 26, 2026 | — | — | |
8-K | Jan 7, 2026 | — | — | |
8-K | Dec 10, 2025 | — | — | |
10-Q | Nov 10, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 11, 2025 | Jun 30, 2025 | — | |
10-Q | May 8, 2025 | Mar 31, 2025 | — | |
10-K | Feb 28, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 13, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 8, 2024 | Jun 30, 2024 | — | |
10-Q | May 9, 2024 | Mar 31, 2024 | — | |
10-K | Feb 29, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 9, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 9, 2023 | Jun 30, 2023 | — | |
10-Q | May 11, 2023 | Mar 31, 2023 | — | |
10-K | Mar 15, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 8, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 11, 2022 | Jun 30, 2022 | — | |
10-Q | May 12, 2022 | Mar 31, 2022 | — | |
10-K | Mar 28, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 10, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 12, 2021 | Jun 30, 2021 | — | |
10-Q | May 13, 2021 | Mar 31, 2021 | — |
Frequently Asked Questions
What are the latest FDMT SEC filings in 2026?
4D Molecular Therapeutics, Inc. (FDMT) has filed a 10-K annual report on March 18, 2026, a 10-Q quarterly report on November 10, 2025, an 8-K current report on March 30, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did FDMT file its most recent 10-K annual report?
4D Molecular Therapeutics, Inc. (FDMT) filed its most recent 10-K annual report on March 18, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view FDMT 10-Q quarterly reports?
4D Molecular Therapeutics, Inc. (FDMT)'s most recent 10-Q quarterly report was filed on November 10, 2025. SignalX displays every FDMT 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has FDMT filed recently?
4D Molecular Therapeutics, Inc. (FDMT)'s most recent 8-K was filed on March 30, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find FDMT insider trading activity (Form 4)?
SignalX aggregates every FDMT Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does FDMT file with the SEC?
4D Molecular Therapeutics, Inc. (FDMT) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new FDMT filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for 4D Molecular Therapeutics, Inc. (FDMT).
What is FDMT's SEC CIK number?
4D Molecular Therapeutics, Inc. (FDMT)'s SEC CIK (Central Index Key) number is 1650648. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1650648 to look up all FDMT filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find FDMT return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from 4D Molecular Therapeutics, Inc. (FDMT) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of 4D Molecular Therapeutics, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 26+ filings.